Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Use of quinine and mortality-risk in patients with heart failure-a Danish nationwide observational study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Tramadol use in Norway: A register-based population study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Multi-centre, multi-database studies with common protocols: Lessons learnt from the IMI PROTECT project

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hypnotics and mortality--partial confounding by disease, substance abuse and socioeconomic factors?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The use of valproic acid and multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Polygenic predisposition to breast cancer and the risk of coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Rate and rhythm therapy in patients with atrial fibrillation and the risk of pacing and bradyarrhythmia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: Leg cramps are common in patients with heart failure. Quinine is frequently prescribed in low doses to these patients, but safety of this practice is unknown. We studied the outcomes associated with use of quinine in a nationwide cohort of patients with heart failure.

METHODS: Through individual-level-linkage of Danish national registries, we identified patients discharged from first-time hospitalization for heart failure in 1997-2010. We estimated the risk of mortality associated with quinine treatment by time-dependent Poisson regression models.

RESULTS: A total of 135 529 patients were included, with 14 510 patients (11%) using quinine at some point. During a median time of follow-up of 989 days (interquartile range 350-2004) 88 878 patients (66%) died. Patients receiving quinine had slightly increased mortality risk, adjusted incidence rate ratio (IRR) 1.04 (95% confidence interval [CI] 1.01 to 1.07). The risks differed according to concomitant β-blocker treatment. For patients treated with both quinine and β-blockers IRR was 1.15 (95% CI 1.09 to 1.21) vs. 0.99 (95% CI 0.96 to 1.03) for patients treated with quinine but not β-blockers. The risks were highest shortly after initiation of therapy: for the first 14 days of treatment IRR was 2.12 (95% CI 1.54 to 2.93) for patients in treatment with β-blockers and 1.17 (95% CI 0.86 to 1.59) for patients not treated with β-blockers.

CONCLUSIONS: Use of quinine was common and associated with increased mortality in heart failure, especially if administered together with β-blockers and shortly after treatment initiation. Mechanisms underlying the findings remain to be established. Copyright © 2015 John Wiley & Sons, Ltd.

OriginalsprogEngelsk
TidsskriftPharmacoepidemiology and Drug Safety
Vol/bind24
Udgave nummer3
Sider (fra-til)310-8
ISSN1053-8569
DOI
StatusUdgivet - 4 feb. 2015

ID: 44982378